Reports Q4 revenue $37.55B, consensus $35.75B. “Our financial results in the fiscal fourth quarter and full year 2024 reflected our disciplined execution on cost management, working capital initiatives and capex reduction. In fiscal 2025, we are focusing on stabilizing the retail pharmacy by optimizing our footprint, controlling operating costs, improving cash flow, and continuing to address reimbursement models to support dispensing margins and preserve patient access for the future,” said Tim Wentworth, Chief Executive Officer, Walgreens Boots Alliance. “Fiscal 2025 will be an important rebasing year as we advance our strategy to drive value creation. This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- Notable companies reporting before tomorrow’s open
- Unusually active option classes on open October 14th
- Walgreens Boots Alliance (WBA) Q4 Pre-Earnings: Here’s What to Expect
- Options Volatility and Implied Earnings Moves This Week, October 15 – October 18, 2024
- WBA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
